<DOC>
	<DOCNO>NCT01000844</DOCNO>
	<brief_summary>The original Joint Outcome Study ( JOS ) enrol 65 boy hemophilia 16 site nationally . The subject randomize one two arm ( prophylaxis enhance episode-based treatment ) follow prospectively age six . At age six , proportion child treatment arm develop bone cartilage damage determine X-Ray MRI assess . In addition , function structure index joint ( define knee , ankle , elbow ) evaluate use physical assessment scale specially design preschool child . The specific aim Joint Outcome Study Continuation ( JOSC ) extend observation child participate original JOS subject reach age 18 year order determine natural history joint development hemophilia impact primary secondary prophylaxis prevention , limitation , reversal hemophilic arthropathy . In addition , plasma DNA collect bank yearly current future study biomarkers predictor hemophilia outcome .</brief_summary>
	<brief_title>Joint Outcome Study Continuation Children With Severe Factor VIII Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Enrolled original JOS study , `` A Randomized Prospective Study Prevention Joint Disease Children Factor VIII Deficiency '' Written , inform consent parent guardian propose study The local hemophilia treatment center staff must evaluate family 's participation original treatment protocol determine family capable comply continuation protocol Unable unwilling record study information</criteria>
	<gender>Male</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Joint</keyword>
	<keyword>Cartilage</keyword>
	<keyword>Damage</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>FVIII</keyword>
	<keyword>Disease</keyword>
	<keyword>Arthropathy</keyword>
</DOC>